Understanding prostate cancer care: recent progress and future direction
The introduction of MRI-guided diagnostic pathways and novel PARP inhibitors hold promise for improving prostate cancer screening and personalized treatment, potentially reducing disease burden worldwide.
This editorial reviews the latest developments in prostate cancer care, emphasizing advances in MRI-based screening, the role of genomics and PARP inhibition in personalized therapy, and the challenges posed by health disparities and evolving demographics.
Prostate cancer remains a major global health burden; enhancing screening accuracy and therapeutic options can improve survival, reduce morbidity, and address inequities in care.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience